Datapoint: Fotivda Scores Kidney Cancer Nod

The FDA last week approved Aveo Oncology’s Fotivda as a third-line treatment for kidney cancer, following years of regulatory hurdles. Pfizer’s Sutent is one of the most advantaged drugs in the kidney cancer space, holding preferred formulary placement for 20% of covered lives, growing to 52% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 3/17/21

0

0

0 Comments

0

0

• Datapoint